Takashi Naito1,2,3, Manabe Shun4,5, Hideki Nishimura6, Tomoki Gibo4,5, Mai Tosaka4,5, Moe Kawashima4,5, Akitoshi Ando4, Tetsuya Ogawa6, Tsutomu Sanaka7, Kosaku Nitta5. 1. Department of Medicine, Tokyo Rosai Hospital, Tokyo, Japan. takashi020304@yahoo.co.jp. 2. Department of Medicine, Medical Center East, Tokyo Women's Medical University, Tokyo, Japan. takashi020304@yahoo.co.jp. 3. Hiyoshi Sezai Clinic, 2-5-2-4F, Hiyoshi, Kohokuku, Yokohama, Kanagawa, 223-0061, Japan. takashi020304@yahoo.co.jp. 4. Department of Medicine, Tokyo Rosai Hospital, Tokyo, Japan. 5. Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan. 6. Department of Medicine, Medical Center East, Tokyo Women's Medical University, Tokyo, Japan. 7. Life Style Disease Center, Edogawa Hospital, Tokyo, Japan.
Abstract
BACKGROUND: Recent studies have suggested that erythropoiesis-stimulating agents (ESAs) may accelerate not only angiogenesis but also vasculogenesis, beyond erythropoiesis. METHODS: We conducted a 12-week prospective study in 51 dialysis patients; 13 were treated with recombinant human erythropoietin (EPO, 5290.4 ± 586.9 IU/week), 16 with darbepoetin (DA, 42.9 ± 4.3 µg/week), 12 with epoetin β pegol (CERA, 40.5 ± 4.1 µg/week) and 10 with no ESAs. Vascular mediators comprising endothelial progenitor cells (EPCs), vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2), and high-sensitivity C-reactive protein (hs-CRP) were measured at 0 and 12 weeks. EPCs were measured by flow cytometry as CD45lowCD34+CD133+ cells. RESULTS: The EPC count increased significantly to a greater extent in the EPO group than in the other three group, and increased significantly from 0 to 12 weeks in a EPO dose-dependent manner. In both the DA and CERA groups, the EPC count did not change at 12 weeks. Serum levels of VEGF, MMP-2 and hs-CRP were not affected by ESA treatment in all groups. In the CERA group, serum ferritin decreased significantly compared to the no-ESA group and correlated with CERA dose, although use of iron was permitted if required during the prospective study period of 12 weeks. CONCLUSIONS: When patients on dialysis were treated with clinical doses of various ESAs, only EPO induced a significant increase of circulating EPCs from bone marrow, whereas, DA and CERA had no effect.
BACKGROUND: Recent studies have suggested that erythropoiesis-stimulating agents (ESAs) may accelerate not only angiogenesis but also vasculogenesis, beyond erythropoiesis. METHODS: We conducted a 12-week prospective study in 51 dialysis patients; 13 were treated with recombinant human erythropoietin (EPO, 5290.4 ± 586.9 IU/week), 16 with darbepoetin (DA, 42.9 ± 4.3 µg/week), 12 with epoetin β pegol (CERA, 40.5 ± 4.1 µg/week) and 10 with no ESAs. Vascular mediators comprising endothelial progenitor cells (EPCs), vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2), and high-sensitivity C-reactive protein (hs-CRP) were measured at 0 and 12 weeks. EPCs were measured by flow cytometry as CD45lowCD34+CD133+ cells. RESULTS: The EPC count increased significantly to a greater extent in the EPO group than in the other three group, and increased significantly from 0 to 12 weeks in a EPO dose-dependent manner. In both the DA and CERA groups, the EPC count did not change at 12 weeks. Serum levels of VEGF, MMP-2 and hs-CRP were not affected by ESA treatment in all groups. In the CERA group, serum ferritin decreased significantly compared to the no-ESA group and correlated with CERA dose, although use of iron was permitted if required during the prospective study period of 12 weeks. CONCLUSIONS: When patients on dialysis were treated with clinical doses of various ESAs, only EPO induced a significant increase of circulating EPCs from bone marrow, whereas, DA and CERA had no effect.
Authors: Christopher Heeschen; Alexandra Aicher; Ralf Lehmann; Stephan Fichtlscherer; Mariuca Vasa; Carmen Urbich; Christiane Mildner-Rihm; Hans Martin; Andreas M Zeiher; Stefanie Dimmeler Journal: Blood Date: 2003-04-17 Impact factor: 22.113
Authors: Y Le Meur; V Lorgeot; L Comte; J C Szelag; J C Aldigier; C Leroux-Robert; V Praloran Journal: Am J Kidney Dis Date: 2001-09 Impact factor: 8.860
Authors: Ferdinand H Bahlmann; Kirsten De Groot; Jens-Michael Spandau; Aimee L Landry; Barbara Hertel; Thorsten Duckert; Sascha M Boehm; Jan Menne; Hermann Haller; Danilo Fliser Journal: Blood Date: 2003-10-02 Impact factor: 22.113